IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceDate/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate ContactGlenn Schulman, PharmD, MPHIN8bio, Inc.203.494.7411gdschulman@IN8bio.com
Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency
Roper Technologies, Inc. (NASDAQ:ROP) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. A software developer looking out a window while confidently typing away on their laptop. Roper Technologies, Inc. (NASDAQ:ROP) is a group of technology businesses that hold strong positions in specialized niche markets. Its portfolio includes application software, network software, and technology-enabled products, all designed to deliver essential solutions that become deeply integrated into customers' operations. These offerings typically lead to high switching costs and generate steady, recurring revenue. In the second quarter of 2025, Roper Technologies, Inc. (NASDAQ:ROP) reported a 13.2% increase in revenue, driven by 7% organic growth and a 6% boost from recent acquisitions. GAAP net earnings rose by 12%. Management pointed to balanced growth across all major segments, crediting strong product innovation, successful integration of past acquisitions, and ongoing demand for recurring software solutions. Roper Technologies, Inc. (NASDAQ:ROP) has garnered investor attention because the company has a strong dividend policy. On June 11, the company declared a quarterly dividend of $0.825 per share, which was in line with its previous dividend. Overall, it has raised its payouts for 33 consecutive years, which makes ROP one of the best dividend stocks to buy and hold. The stock has a dividend yield of 0.60%, as of July 31. While we acknowledge the potential of ROP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements. The median positive return has been 3.0%, with a maximum one-day increase of 9.0%. For those trading based on events, recognizing these historical trends can prove advantageous, although actual performance against expectations will be crucial. There are two primary strategies to think about: Analysts anticipate Vertex will disclose earnings of $4.25 per share, generating a revenue of $2.91 billion. This marks a considerable improvement compared to the same quarter last year, which reported a loss of $12.83 per share on sales of $2.65 billion. However, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. View earnings reaction history of all stocks Vertex Pharmaceuticals' Historical Probability of Positive Post-Earnings Return Some insights regarding one-day (1D) post-earnings returns: Further information on observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized in the table below along with the related statistics. Correlation Between 1D, 5D and 21D Historical Returns A comparatively lower-risk approach (though not effective if the correlation is weak) is to evaluate the correlation between short-term and medium-term returns after earnings, identify the pair that exhibits the strongest correlation, and perform the proper trade. For instance, if 1D and 5D display the highest correlation, a trader can place themselves "long" for the forthcoming 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on both a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D indicates the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (the combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for stakeholders. Additionally, if you're seeking upside with a more stable journey than an individual stock like Vertex Pharmaceuticals, think about the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception.
Business Insider
2 hours ago
- Business Insider
Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity
In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Alphatec Holdings, with a price target of $20.00. The company's shares closed today at $13.77. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cronin is a 2-star analyst with an average return of 0.5% and a 45.74% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Vericel, and Orthofix. In addition to Canaccord Genuity, Alphatec Holdings also received a Buy from Lake Street's Ben Haynor in a report issued today. However, on July 30, TR | OpenAI – 4o reiterated a Hold rating on Alphatec Holdings (NASDAQ: ATEC). Based on Alphatec Holdings' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $169.18 million and a GAAP net loss of $51.91 million. In comparison, last year the company earned a revenue of $138.48 million and had a GAAP net loss of $48.5 million Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year. Most recently, in May 2025, Scott Lish, the COO of ATEC sold 12,000.00 shares for a total of $145,440.00.
